Generative AI in Drug Discovery Market (By Technology: Machine Learning, Reinforcement Learning, Deep Learning, Molecular Docking, Quantum Computing; By End User: Pharmaceutical & Biotechnology Company, Academic & Research Institution, Contract Research Organizations, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Generative AI in Drug Discovery Market 

5.1. COVID-19 Landscape: Generative AI in Drug Discovery Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Generative AI in Drug Discovery Market, By Technology

8.1. Generative AI in Drug Discovery Market, by Technology, 2023-2032

8.1.1. Machine Learning

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Reinforcement Learning

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Deep Learning

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Molecular Docking

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Quantum Computing

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Generative AI in Drug Discovery Market, By End User

9.1. Generative AI in Drug Discovery Market, by End User, 2023-2032

9.1.1. Pharmaceutical & Biotechnology Company

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Academic & Research Institution

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Contract Research Organizations

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Generative AI in Drug Discovery Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Technology (2020-2032)

10.1.2. Market Revenue and Forecast, by End User (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.1.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.1.4.2. Market Revenue and Forecast, by End User (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Technology (2020-2032)

10.2.2. Market Revenue and Forecast, by End User (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.2.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.2.4.2. Market Revenue and Forecast, by End User (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)

10.2.5.2. Market Revenue and Forecast, by End User (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)

10.2.6.2. Market Revenue and Forecast, by End User (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.3.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.3.4.2. Market Revenue and Forecast, by End User (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)

10.3.5.2. Market Revenue and Forecast, by End User (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)

10.3.6.2. Market Revenue and Forecast, by End User (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.4.2. Market Revenue and Forecast, by End User (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.4.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.4.4.2. Market Revenue and Forecast, by End User (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)

10.4.5.2. Market Revenue and Forecast, by End User (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)

10.4.6.2. Market Revenue and Forecast, by End User (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Technology (2020-2032)

10.5.2. Market Revenue and Forecast, by End User (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Technology (2020-2032)

10.5.3.2. Market Revenue and Forecast, by End User (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Technology (2020-2032)

10.5.4.2. Market Revenue and Forecast, by End User (2020-2032)

Chapter 11. Company Profiles

11.1. Insilico Medicine

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Atomwise Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. BenevolentAI

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. XtalPi Inc

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Numerate Inc

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Cyclica Inc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. BioSymetrics

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Variational AI Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Variational AI Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. NVIDIA

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample